Michael Soeberdt Selected Research

Michael Soeberdt Research Topics

4	Skin Diseases (Skin Disease) 01/2024 - 01/2019
4	Inflammation (Inflammations) 01/2019 - 01/2017
3	Atopic Dermatitis (Atopic Eczema) 01/2022 - 01/2019
3	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2020 - 01/2017
2	Pruritus (Itching) 01/2022 - 08/2020
2	Hyperhidrosis 01/2020 - 01/2019
1	Dermatitis 01/2022
1	Neurogenic Inflammation 08/2020
1	Acne Vulgaris 01/2020
1	Alopecia Areata 01/2020
1	Central Nervous System Diseases (CNS Diseases) 01/2019
1	Peptic Ulcer (Peptic Ulcers) 01/2019
1	Chronic Obstructive Pulmonary Disease (COPD) 01/2019
1	Hyperalgesia 08/2014

2	Opioid Receptors (Opioid Receptor)IBA 01/2022 - 08/2020
2	asimadolineIBA 01/2022 - 01/2019
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	AllergensIBA 01/2022
1	Opioid Analgesics (Opioids)IBA 01/2022
1	Janus Kinase InhibitorsIBA 08/2020
1	Neurokinin-1 Receptors (Neurokinin 1 Receptor)IBA 08/2020
1	Phosphodiesterase 4 InhibitorsIBA 08/2020
1	Synthetic DrugsIBA 01/2020
1	Fingolimod Hydrochloride (FTY720)FDA Link 01/2019
1	glycolic acid (glycolate)IBA 01/2019
1	WOL067-531IBA 01/2019
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019
1	Monoclonal AntibodiesIBA 01/2019
1	BuffersIBA 01/2019
1	CannabidiolIBA 01/2019
1	Glycopyrrolate (Glycopyrronium Bromide)FDA LinkGeneric 01/2019
1	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)IBA 01/2019
1	EndocannabinoidsIBA 01/2019
1	Calcineurin InhibitorsIBA 01/2019
1	alpha-MSHIBA 01/2017
1	CytokinesIBA 01/2017
1	Imiquimod (Aldara)FDA LinkGeneric 01/2017
1	KdPT tripeptideIBA 01/2017
1	methanesulfonamideIBA 01/2017
1	Amino Acids FDA Link 01/2017
1	Analgesics (Analgesic Drugs)IBA 08/2014

2	Therapeutics 08/2020 - 01/2020
1	Topical Administration 01/2024